000			01438 a2200397 4500
005			20250515152822.0
264		0	_c20090623
008			200906s 0 0 eng d
022			_a1872-7980
024	7		_a10.1016/j.canlet.2008.11.019 _2doi
040			_aNLM _beng _cNLM
100	1		_aGlauben, Rainer
245	0	0	_aHDAC inhibitors in models of inflammation-related tumorigenesis. _h[electronic resource]
260			_bCancer letters _cAug 2009
300			_a154-9 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAcetylation
650	0	4	_aAnimals
650	0	4	_aAnti-Inflammatory Agents _xtherapeutic use
650	0	4	_aAnticarcinogenic Agents _xtherapeutic use
650	0	4	_aCD4-Positive T-Lymphocytes _ximmunology
650	0	4	_aCell Transformation, Neoplastic _xdrug effects
650	0	4	_aColitis _xdrug therapy
650	0	4	_aColonic Neoplasms _ximmunology
650	0	4	_aHistone Deacetylase Inhibitors
650	0	4	_aHistone Deacetylases _xmetabolism
650	0	4	_aHumans
650	0	4	_aInflammation _xdrug therapy
650	0	4	_aNF-kappa B _xmetabolism
650	0	4	_aNeoplasms _xdrug therapy
700	1		_aSonnenberg, Elena
700	1		_aZeitz, Martin
700	1		_aSiegmund, Britta
773	0		_tCancer letters _gvol. 280 _gno. 2 _gp. 154-9
856	4	0	_uhttps://doi.org/10.1016/j.canlet.2008.11.019 _zAvailable from publisher's website
999			_c18551927 _d18551927